secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001683168-23-000500
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech authorizes new $10M share repurchase program
---------------------------------------------------------------

- Board authorized repurchase of up to $10M of common stock, effective immediately for two years.
- Prior program (June 2022) repurchased ~3.41M shares for ~$9.3M as of filing date.
- Program will be funded from available cash; CEO cites strong balance sheet and shareholder commitment.
- Company continues evaluating internal programs and exploring strategic opportunities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/0001683168-23-000500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823000500/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-000500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer